Literature DB >> 10381276

N(epsilon)-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress.

A G Nerlich1, E D Schleicher.   

Abstract

Previous studies suggested that N(epsilon)-(carboxymethyl)lysine (CML), as the major product of oxidative degradation of glycated proteins and unsaturated fatty acids, represents an integrative biomarker for oxidative stress. In the present study, the level of CML in morphologically normal as well as atherosclerotic vessel walls are immunohistochemically analyzed and the in vitro formation of CML determined from glycoxidation and lipid peroxidation processes. The analysis revealed negative staining results in normal arterial walls of fetal, juvenile and young adult origin. A minor positive staining was seen in normal arteries from adults between 40 and 60 years of age with a rise in the CML-staining further increasing with rising individual age. This staining was mainly restricted to the intimal extracellular matrix and there was no intracellular staining. In arteriosclerotic vessels, in contrast, the extracellular CML-staining was significantly increased by approximately 3-fold also affecting the vascular media and adventitia. A strong intracellular staining was seen in macrophages. The degree of CML-staining correlated with the extent of the atherosclerotic changes. The in vitro studies showed a slow formation of CML of glycated proteins under aerobic conditions. No CML was formed under anaerobic conditions. Unsaturated fatty acids revealed a much faster formation of CML which reached high levels. The addition of vitamin E did not substantially suppress the CML-formation. The data suggest that the endogenous biomarker CML for oxidative stress accumulates slowly in normal arterial walls. This process is significantly increased in atherosclerosis. While the accumulation of CML in the extracellular matrix seemed to be the result of ongoing glycoxidation, the significant intracellular CML-formation in macrophages may have resulted from lipid peroxidation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381276     DOI: 10.1016/s0021-9150(99)00038-6

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  17 in total

1.  Identification of the advanced glycation end products N(epsilon)-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis.

Authors:  S Drinda; S Franke; C C Canet; P Petrow; R Bräuer; C Hüttich; G Stein; G Hein
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 2.  Does accumulation of advanced glycation end products contribute to the aging phenotype?

Authors:  Richard D Semba; Emily J Nicklett; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-17       Impact factor: 6.053

Review 3.  Potential health benefits of phenolic compounds in grape processing by-products.

Authors:  Janice N Averilla; Jisun Oh; Hyo Jung Kim; Jae Sik Kim; Jong-Sang Kim
Journal:  Food Sci Biotechnol       Date:  2019-05-27       Impact factor: 2.391

Review 4.  Atherosclerosis and restenosis: is there a role for RAGE?

Authors:  Peter Nawroth; Angelika Bierhaus; Mario Marrero; Hiroshi Yamamoto; David M Stern
Journal:  Curr Diab Rep       Date:  2005-02       Impact factor: 4.810

Review 5.  RAGE: a novel target for drug intervention in diabetic vascular disease.

Authors:  Barry I Hudson; Ann Marie Schmidt
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

Review 6.  The role of advanced glycation end products in the development of atherosclerosis.

Authors:  Melpomeni Peppa; Jaime Uribarri; Helen Vlassara
Journal:  Curr Diab Rep       Date:  2004-02       Impact factor: 4.810

7.  Use of human vascular tissue microarrays for measurement of advanced glycation endproducts.

Authors:  Marc K Halushka; Elizabeth Selvin; Jie Lu; Anne M Macgregor; Toby C Cornish
Journal:  J Histochem Cytochem       Date:  2009-02-16       Impact factor: 2.479

8.  Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice.

Authors:  A M E Bruynzeel; M A Abou El Hassan; C Schalkwijk; J Berkhof; A Bast; H W M Niessen; W J F van der Vijgh
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640

Review 9.  Advanced glycation end products and oxidative stress in type 2 diabetes mellitus.

Authors:  Kerstin Nowotny; Tobias Jung; Annika Höhn; Daniela Weber; Tilman Grune
Journal:  Biomolecules       Date:  2015-03-16

10.  N(epsilon)-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status.

Authors:  Khaled A Ahmed; Sekaran Muniandy; Ikram S Ismail
Journal:  J Clin Biochem Nutr       Date:  2008-12-27       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.